

Resveratrol as an immune checkpoint inhibitor to enhance the efficacy of breast cancer immunotherapy

Nafiseh Sadat Alamolhodaei ¹, Barry I. Hudson ², Fatemeh Mosaffa ³, Motahareh Boozari ^{4*}

¹ Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

² Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC, United States

³ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

⁴ Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

ARTICLE INFO

Article type:

Review

Article history:

Received: Dec 13, 2025

Accepted: Jun 2, 2026

Keywords:

Breast cancer
Immune cells
Immunotherapy
Natural products
PD-1/PD-L1
Resveratrol
Tumor microenvironment

ABSTRACT

A major goal in cancer treatment is to convert “cold” tumors into “hot” ones by altering the tumor microenvironment (TME). Breast cancer is often a cold tumor and is resistant to immunotherapy. Resveratrol is a polyphenolic compound found in grapes, with antioxidant, anti-inflammatory, and potential cardioprotective and anti-aging properties. Resveratrol promotes the conversion of immunologically cold breast tumors into hot tumors, thereby increasing the efficacy of immunotherapy. This article reviews the potential of resveratrol to convert immunologically “cold” breast tumors into “hot” tumors by modulating the TME and enhancing the efficacy of immunotherapy. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar to identify English-language articles investigating the effects of resveratrol on immune checkpoints in breast cancer. The results showed that resveratrol suppresses key cancer-promoting pathways (PI3K/Akt/mTOR, MAPK/ERK, STAT/NF- κ B, and Wnt/ β -catenin) and modulates the immune system. It boosts anti-tumor immunity by activating immunostimulatory cells (such as M1-TAMs, NKs, and CTLs) while simultaneously inhibiting immunosuppressive cells (such as Tregs and MDSCs). It also acts as a natural immune checkpoint inhibitor by targeting the PD-1/PD-L1 pathway. Resveratrol prevents T-cell exhaustion in “cold” tumors and reduces PD-L1 expression in “hot” tumors, thereby enhancing cytotoxic T cells’ ability to attack cancer. However, its effectiveness is limited by poor bioavailability and differences in the biological activity of its metabolites. Future clinical studies are needed to confirm these results and determine optimal therapeutic protocols for resveratrol-mediated breast cancer immunotherapy.

► Please cite this article as:

Alamolhodaei NS, Hudson BI, Mosaffa F, Boozari M. Resveratrol as an immune checkpoint inhibitor to enhance the efficacy of breast cancer immunotherapy. Iran J Basic Med Sci 2026; 29: 1631-1647. doi: <https://dx.doi.org/10.22038/ijbms.2026.93534.20178>

Introduction

Breast cancer, which is highly prevalent in women, is characterized by remarkably diverse malignancy (1). Breast cancer contains a range of biological subtypes with various treatment responses, and clinical outcomes. Despite the availability of targeted therapies, treatment resistance remains a significant challenge (2). The tumor microenvironment (TME) is a complex and active system of tumor cells, stromal cells, and extracellular matrix. The TME influences tumor progression and treatment efficacy through environmental signals, including chemokines, growth factors, tumor-related cytokines, and metabolic products (3). Immune cells play a pivotal role in organizing anti-tumor immune responses in TME (4, 5). Immune cells often include innate immune cells such as macrophages, neutrophils, adaptive immune cells (T and B cells), dendritic cells (DCs), natural killer cells (NK cells), and bone marrow-derived suppressor cells (6). Nevertheless, in some cases, immune cells can have two distinct roles: they can either stimulate anti-tumor responses or facilitate

immunosuppressive responses. This duality depends on the complex interactions among signals in the TME (7, 8). This novel view of immune evasion has improved approaches to cancer therapy, particularly by using immune cells to combat cancer cells (9). Tumors based on the presence of tumor-infiltrating lymphocytes (TILs) are categorized as “hot” (inflamed) or “cold” (non-inflamed). A significant challenge in oncology is converting immunologically cold tumors into hot ones to sensitize them to immunotherapy. This transformation requires a multi-faceted approach targeting key mechanisms within the TME (Figure 1).

Cancer immunotherapy has revolutionized oncology by providing novel therapeutic approaches. The major cancer immunotherapies include adoptive cell therapy (ACT), chimeric antigen receptor T-cells (CAR-T), T-cell receptor (TCR) engineering, monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs) (10). Cancer immunotherapy works by boosting the immune system's innate ability to fight cancer and to target tumor cells (11, 12). A pre-existing anti-tumor immune response is critical to the

*Corresponding author: Motahareh Boozari. Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Email: boozarim1367@gmail.com, bouzarim@mums.ac.ir



© 2026. This work is openly licensed via [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Impact of ICIs and the PD-1/PD-L1 pathway on converting cold tumors to hot tumors

ICIS: Immune checkpoint inhibitors; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; TMB: tumor mutational burden; ICIs: immune checkpoint inhibitors

efficacy of cancer immunotherapy and immune checkpoint inhibitors (ICIs). Immune checkpoints are regulators of the immune system. Certain tumors can activate immune checkpoint pathways and evade the immune response. ICIs have demonstrated critical therapeutic effects on a diverse range of malignancies. Currently approved ICIs primarily inhibit the T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) pathways. PD-1 is a receptor on the surface of immune cells, primarily T-cells. PD-1 prevents T cells from attacking healthy cells, thereby inhibiting autoimmune diseases. PD-L1 is a ligand on the surface of healthy cells, tumor cells (in cancer), and other cells in the TME. PD-L1 acts as the signal that tells the T-cell to shut down. Cancer cells exploit PD-L1 to evade the immune response. Cancer cells exploit immune checkpoint pathways by overexpressing PD-L1 on their surface. This ligand binds to the PD-1 receptor on activated T-cells. This interaction suppresses T-cell effector functions and enables tumor cells to evade immune-mediated destruction (13). Several immunotherapy strategies have been explored for breast cancer, with a focus on ICIs (14). Cancers that respond well to ICIs generally display at least one of the following three important properties: a significant number of tumor-infiltrating lymphocytes (TILs), elevated PD-L1 expression, and a high tumor mutational burden (TMB) (15).

Despite the potential of immunotherapy for cancer treatment, its success in breast cancer has been limited, especially for patients with metastatic breast cancer (16). The complexity of TME signaling is a key challenge in developing effective cancer immunotherapy (17). Moreover, combining chemotherapy and radiotherapy can enhance the efficacy of immunotherapy (18).

A novel strategy for improving immunotherapy efficacy in breast cancer involves the use of natural products with immunomodulatory properties (19-22). Various natural

compounds have shown significant effects in breast cancer immunotherapy by inhibiting Epithelial-Mesenchymal Transition (EMT) and PD-L1 (23, 24).

Resveratrol (3,4',5-trihydroxystilbene) is a stilbene polyphenol naturally synthesized in plants such as red grapes, berries, and nuts (25). Resveratrol regulates immune responses through direct effects on innate and adaptive immunity and indirect effects by sensitizing tumor cells to immune cells (20, 26, 27). Resveratrol is a promising candidate for breast cancer therapy due to its ability to modulate immune responses (21, 26). Combining resveratrol with standard treatments that target the PD-1/PD-L1 pathway is a promising approach to enhance anti-tumor effects in breast cancer therapy (28-30).

This review explains the role of immunotherapy in breast cancer and investigates the impact of resveratrol on TME and immunotherapy. Additionally, it discusses the potential of resveratrol to act synergistically with anti-PD-1/PD-L1 immunotherapy to improve treatment outcomes for breast cancer patients.

Research methods

A comprehensive literature search was conducted in 2025 using the databases PubMed, Scopus, Web of Science, and Google Scholar. The search strategy employed the following keywords combined with operators: ("Resveratrol") AND ("Breast Cancer") AND ("Immune Checkpoint Inhibitors") OR "PD-1" OR "PD-L1" OR "CTLA-4". All English-language articles investigating the effects of resveratrol on immune checkpoints in the context of breast cancer were included in the review.

Results

Common breast cancer therapies such as chemotherapy, radiation, and surgery often yield limited results and cause




Figure 2. *trans*- and *cis*-configurations of resveratrol

considerable side effects (13). Additionally, metastatic breast cancer remains incurable (31). Immunotherapy could be a new approach to treating breast cancer. Several immunotherapy strategies have been investigated for the treatment of breast cancer, including adoptive T-cell therapy, tumor-targeting antibodies, cytokine/chemokine-based immunotherapies, vaccines, and innate immune agonists. Notably, PD-1/PD-L1 inhibitors represent the most widely studied strategy (14, 32).

A key challenge is that breast tumors are typically non-immunogenic (cold tumors). This means they have a low number of mutations (low TMB), few lymphocytes (low TILs), and low PD-L1 levels. Consequently, they typically respond poorly to immunotherapies, including ICI (15).

Many studies investigating breast cancer immunotherapy have focused on PD-1/PD-L1 inhibition (33-35).

Clinically, the monoclonal antibody pembrolizumab (a PD-1 inhibitor) has been approved for metastatic triple-negative breast cancer (TNBC). However, its use is typically limited to cases with high PD-L1 expression (32, 36). It is also demonstrated that the combination of antiestrogen with pembrolizumab has shown promise in treating hormone receptor (HR)-positive metastatic breast cancer (37). Moreover, atezolizumab is Food and Drug Administration (FDA)- approved, in combination with chemotherapy, to treat metastatic PD-L1-positive TNBC (34).

ICIs for breast cancer can cause significant side effects. The most common are skin rash (38%), infusion reactions (12%), and hypothyroidism (12%) (38, 39).

Researchers are seeking new ways to make breast tumors more responsive to immunotherapy (40, 41). There is growing interest in natural compounds such as resveratrol,

which may help modulate the immune system, improve long-term outcomes, reduce side effects, and prevent therapy resistance (21, 26, 26).

Immunomodulatory effects of resveratrol

Resveratrol is a natural polyphenolic compound (42). Resveratrol is present in grapes, berries, plums, and even peanuts, but it was originally identified in white hellebore (*Veratrum grandiflorum*) (25). This compound exists primarily in two configurations: *cis*- and *trans*-resveratrol (Figure 2). The more stable isomer is *trans*-resveratrol, which is stable in visible light, high temperature, and low pH (43). The bioavailability of resveratrol is generally low due to rapid metabolism by phase II enzymes in both the intestine and liver, which convert it into 3- and 4'-O-sulfate and 3-O-glucuronide conjugates (44).

Resveratrol has demonstrated various biological effects, including neuroprotective, antibacterial, cardioprotective, anti-diabetic, anti-aging, and estrogenic/anti-estrogenic effects, as well as the prevention and management of obesity and obesity-related metabolic syndrome (43, 45). Anti-tumor properties of resveratrol influence multiple stages of cancer development, including initiation, promotion, and progression. The anti-tumor effects are related to the regulation of various signal-transduction pathways that control cell growth and division, inflammation, apoptosis, metastasis, and angiogenesis (45).

The inflammasome, a multiprotein complex that activates pro-inflammatory cytokines and initiates immune responses, is a critical regulator of inflammation. Resveratrol can act as NLR family pyrin domain containing 3 (NLRP3) inflammasome modulator, an inhibitor of inflammatory signals (nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), interleukin-1 β (IL-1 β), tumor necrosis factor α (TNF- α)), and an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which is a protective pathway against oxidative stress (46).

Resveratrol enhances immunotherapy efficacy through multiple mechanisms. It promotes the release of anticancer cytokines (e.g., interferon γ (IFN- γ), TNF- α) and inhibits immunosuppressive factors like transforming growth factor β (TGF- β). Furthermore, it stimulates the polarization of CD4⁺ T cells and macrophages towards an anticancer response and reduces the presence of immunosuppressive cells. Finally, resveratrol increases cancer cells' susceptibility




Figure 3. Inhibitory mechanisms of resveratrol on key oncogenic signaling pathways (A) PI3K/Akt/mTOR, (B) RAS/RAF/MEK/ERK, (C) JAK/STAT, (D) Wnt/ β -catenin

to the immune response (20).

Current research shows that resveratrol can influence immune cells and PD1/PD-L1 signaling pathway in breast cancer. Resveratrol, through its immunomodulatory effects in the TME (26), can enhance the effectiveness of immunotherapy in breast cancer treatment. This can lead to more effective and less toxic treatments for this disease.

Resveratrol's effect on oncogenic signaling pathways

Resveratrol has been shown to influence the most important signaling pathways related to breast cancer proliferation and metastasis (Figure 3).

Ras/Raf/MEK/ERK (MAPK) signaling pathway

The Ras/Raf/MEK/ERK pathway, or mitogen-activated protein kinase (MAPK) pathway, has been shown to regulate PD-L1 expression in numerous cancer cell types (47-49). A critical effector of the MAPK pathway during cancer progression is extracellular signal-regulated kinase (ERK) (50).

Research using mouse models of breast cancer shows that combining mitogen-activated protein kinase (MEK) inhibitors with PD-1/PD-L1-targeted immunotherapy may improve treatment outcomes. It suggests that the Ras-MAPK pathway helps tumors avoid the immune system in TNBC. Additionally, the activity of the Ras/MAPK pathways and major histocompatibility complex (MHC) expression might help predict how well patients respond to ICIs (51). It was shown that high doses of resveratrol reduced ERK1/2 phosphorylation, however, a study by Lee *et al.* found that resveratrol increased protein kinase B (Akt) signaling but had no effect on phosphorylation of STAT5 or ERK pathways (52). Chen *et al.* found that treating cells with both resveratrol and the drug PD98059 significantly reduced the activity of Ras/Raf/MEK/ERK signaling pathway. By inhibiting this pathway, apoptosis in tumor cells was increased (53).

PI3Ks/Akt/mTOR signaling pathway

Phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) is an important signaling pathway that plays a critical role in cell growth, division, metabolism, suppression of apoptosis, and angiogenesis. The PI3K/AKT/mTOR pathway is a complex intracellular signaling pathway involved in the pathogenesis of various diseases, and its activation contributes to protective effects against cancer and inflammatory diseases (54). The reduction of phosphatase and tensin homolog (PTEN), a crucial tumor suppressor protein, plays a significant role in cancer progression. When PTEN is lost or inactivated, it leads to the oncogenic activation of the PI3K/Akt/mTOR signaling pathway. When PD-L1 is expressed on tumor cells, it can inhibit T-cell activation and allow cancer cells to escape from immune detection. Therefore, the loss of PTEN not only disrupts normal cellular signaling but also enhances tumors' ability to express PD-L1, thereby promoting immune evasion (55).

Messeha *et al.* knocked down the PTEN gene in MDA-MB-231 breast cancer cells, causing the cells to produce more PD-L1 than even after the addition of IFN- γ , a potent inducer of PD-L1 production (23).

Wnt signaling pathway

Wnt signaling is another important pathway in human breast cancer, as it is associated with elevated nuclear and cytoplasmic levels of β -catenin (56). The Wnt signaling pathway involves two main cellular compartments: (i) the cytoplasmic segment includes Disheveled (DVL),

adenomatous polyposis coli (APC), glycogen synthase kinase 3 β (GSK3 β), casein kinase 1 (CK1), and axis inhibition protein (AXIN). This complex constantly breaks down β -catenin and prevents it from building up. (ii) The nucleus mainly contains translocated β -catenin. When Wnt ligands bind to Frizzled receptors, the canonical Wnt signaling pathway is activated, leading to β -catenin-mediated gene transcription (57).

When the Wnt/ β -catenin signaling pathway is overactive in a tumor, it often makes the cancer "cold or non-immunogenic". Overactivation of the Wnt/ β -catenin pathway promotes immune evasion by shielding cancer cells from recognition and attack by T cells in the TME. This leads to poor responses to immunotherapies that try to engage the immune system against the tumor (56).

Resveratrol and related stilbenoids can exert cytotoxic effects on the MCF-7 cell line via the Wnt signaling pathway (58). Resveratrol works by inhibiting cell migration and invasion through dual targeting of the PI3K/Akt and Wnt/ β -catenin pathways, and by reducing matrix metalloproteinase-9 (MMP-9) activity (59, 60).

JAK/STAT signaling pathway

The JAK/STAT pathway is a pivotal signaling mechanism activated by growth factors and cytokines. In this pathway, Janus kinases (JAKs) phosphorylate signal transducers and activators of transcription (STATs) to regulate gene expression. This pathway influences cell growth, survival, differentiation, and immune function, playing a crucial role in cancer progression and immune regulation (61, 62). Specifically, STATs modulate the immune response by regulating PD-L1 expression in TNBC (63). Ma *et al.* hypothesized that resveratrol could suppress JAK/STAT signaling pathways and exhibit anti-inflammatory potential. Their investigation revealed that resveratrol removes the translocation of high mobility group box 1 (HMGB1) from the nucleus to the cytoplasm and NF- κ B (p65) from the cytoplasm to the nucleus (64). Sun *et al.* indicated that STAT3 activation is a crucial regulator of cancer cell proliferation. Resveratrol has been shown to reduce STAT3 activity both *in vitro* and *in vivo* (65).

In most breast cancers, NF- κ B is always active. In normal conditions, NF- κ B stays inactive in the cytoplasm by binding to inhibitor of kappa B (I κ B) proteins, which are controlled by the I κ B kinase (IKK) complex. When I κ B proteins are phosphorylated and degraded, NF- κ B is released and moves to the nucleus. There, it binds to specific DNA sequences, and the p65 subunit activates the transcription of target genes (66). Sustained NF- κ B activation in the TME can lead to chronic inflammation, which promotes tumor growth, survival, metastasis, and resistance to hormone therapy (67).

Based on promising results, it is recommended to use resveratrol, which may inhibit NF- κ B and pro-inflammatory cytokines, in combination with immunotherapeutic agents to treat breast cancer (30, 64). Evidence suggests that resveratrol can inhibit NF- κ B-regulated inflammatory gene products, including MMP-3, MMP-9, cyclooxygenase-2 (COX-2), and vascular endothelial growth factor (VEGF). It also targeted anti-apoptotic proteins B-cell lymphoma-extra large (Bcl-xL), B-cell lymphoma 2 (Bcl-2), and TNF receptor-associated factor 1 (TRAF1), and stimulated cleaved caspase-3 activation (68). Thus, targeting the JAK/STAT and NF- κ B signaling pathways by resveratrol can be a promising therapeutic strategy to improve the prognosis of highly inflammatory TNBC, potentially in combination with other effective inhibitors (66, 69).




Figure 4. Bifunctional modulatory effects of resveratrol on immune cells

(A) Resveratrol has the potential to activate immunostimulatory cells, including M1-TAM, N1-TANs, DCs, NKs, CTLs, and Th1. (B) Resveratrol inhibits the function of immunosuppressive cells, including tBregs, Tregs, Th2 cells, MDSCs, M2-TAMs, and N2-TANs.

tBregs: Tumor-evoked bregs; Tregs: Regulatory T cells; MDSCs: Myeloid-derived suppressor cells

Table 1. Summary of resveratrol anti-cancer and immunomodulatory effects

Treatment	Tumor cell type/ Animal model	Results	Ref.
Study model: Anti-breast cancer effects of resveratrol (<i>in vitro</i>)			
Resveratrol: 25 μ M for 3 days	MDA-MB-231	Significant IL-6/pSTAT3 pathway inhibition	(71)
	MDA-MB-231-cisplatin resistance T47D	Modulation of M1/M2 macrophage polarization to increase M1 markers ↓ Breast cancer cell growth	
Resveratrol: 100 μ mol/l for 24 hr	Basal-like/HER2 ⁺ highly aggressive breast cancer cells (JIMT-1, MDA-MB-231 cell line)	Promotion of anti-tumor T cell response by altering PD-L1 glycosylation and dimerization	(100)
		Lowering the cytotoxicity threshold of tumors for T cell attack Preventing the suppression and exhaustion of anti-tumor immunity	
Resveratrol: 6.25 μ M or 25 μ M for 48 hr	MDA-MB-231, BT-474, BCap37, MDA-MB-468, Hs 578T, SKBR-3, & MCF-7 cell lines	Induction of MICA/B expression through suppression of the c-Myc/miR-17 regulatory pathway	(107)
		Increased cytolytic activity of NK cells demonstrated safety in murine models ↑ Anti-tumor immunity in breast cancer patients	
Resveratrol: 0.625-1280 μ M for 24 or 48 hr + Curcumin: 0.625-1280 μ M for 24 or 48 hr	MDA-MB-231 and MCF7	Resveratrol (IC ₅₀ :134.10 μ M) and Curcumin (IC ₅₀ :12.60 μ M) Resveratrol and curcumin inhibit breast cancer cells growth	(126)
		Downregulating the oncogenic lncRNA MAPT-IT1 pathway Autophagy and ferroptosis pathways activation Resveratrol and curcumin inhibit breast cancer cell proliferation	
Resveratrol: 6.25 μ M, 12.5 μ M, and 25 μ M for 48 hr	MDA-MB-231, BCap37, MCF7, MDA-MB-468 and HeLa	Resveratrol treatment significantly upregulates ULBP(NKG2D receptor activator)	(127)
		Resveratrol downregulates miR-17-5p and induces MINK1 gene Resveratrol increased MINK1 protein and activates the JNK/c-Jun signaling pathway Resveratrol activates NK cell immune response	
Resveratrol: 2-128 μ g/ml for 1-3 days	BT-549	Resveratrol (IC ₅₀ :40.55 $\pm$ 3.39 μ g/ml) Breast cancer cell growth, invasion, and metastasis inhibition	(128)
		apoptosis induction PGK1 enzyme expression reduction by regulating the transcription factor c-Myc Breast cancer treatment through the PGK1 glycolytic pathway	

Continued Table 1.

		Fatty Acid Synthase (FASN) downregulation with siRNA	
Resveratrol: 0-200 μM for 24 and 48 hr	SK-BR-3 (HER2+), MCF-7, and MDA-MB-231	Apoptosis induction	
		Focal adhesion kinase (FAK)/Akt/ERK1/2 inhibition	
		Induces apoptosis in different breast cancers by FASN pathway inhibition	
Study model: Anti-breast cancer effects of resveratrol (<i>in vivo</i>)			
		Resveratrol (IC ₅₀ : 69.62 mg/ml), Curcumin (IC ₅₀ : 79.32 mg/ml), Quercetin (IC ₅₀ : 114.3 mg/ml)	
Resveratrol + Curcumin + Quercetin in different concentrations intragastric administration before (15/30 days) and after inoculation (30 days)	4T1- breast cancer-bearing	Elevation of ROS-mediated apoptosis in cancer cells	
		Elevated levels of CD4 ⁺ and CD8 ⁺ T cells in the TME	
		Inhibition of Th2 cells, M2 macrophages, and N2 neutrophils	
		↑ Immune response in the breast TME	
Resveratrol: 12.5 mg/kg or 25 mg/kg per body weight via IP for 21 days	4T1- tumor-bearing mice	Enhancement of the cytotoxicity of CD8 ⁺ T cells and Th1 immune responses	
		Elevated secretion of IFN-γ, IL-2, perforin, granzyme B	
		Promotion of M1 macrophage polarization	
		Lower the PD-1 expression on lung-resident CD8 ⁺ and CD4 ⁺ T cells	
		No impact observed on cytokines IL-10 and TGF-β or pulmonary MDSCs	
		Suppression of TNBC lung metastasis and growth	
		STAT3 inactivation	
		Blocking tBreg formation and function	
Resveratrol: 50 μg/mouse via IP every other day from days 3 to 11	4T1-tumor-bearing mice	Reducing TGF-β synthesis to inhibit tBreg-induced Treg conversion	
		No impact on MDSC function	
		Facilitating PPAR-α inactivation and blocking B cell conversion to tBregs	
		↓ tBreg-mediated breast cancer progression and metastasis	
Resveratrol: 0, 25 or 100 mg/kg/day IP for 28 days	BCap37 tumor-bearing mice	Induction of MICA/B expression through suppression of the c-Myc/miR 17 regulatory pathway	
		Increased cytolytic activity of NK cells demonstrated safety in murine models	
		↑ Anti-tumor immunity in breast cancer patients	
Resveratrol: 25 mg/kg/day and 100 mg/kg/day IP for 28 days	MDA-MB-231 cells were inoculated into female BALB/c immunodeficient mice	Resveratrol treatment significantly upregulates ULBP (NKG2D receptor activator)	
		Resveratrol downregulates miR-17-5p and induces MINK1gene	
		Resveratrol increased MINK1 protein and activates the JNK/c-Jun signaling pathway	
		Resveratrol activates NK cell immune response	
		Breast cancer cell growth, invasion, and metastasis inhibition	
Resveratrol: 20, 50, and 100 mg/kg body weight/day IP for 21 days	4T1-tumor-bearing mice	apoptosis induction	
		PGK1 enzyme expression reduction by regulating the transcription factor c-Myc	
		Breast cancer treatment through the PGK1 glycolytic pathway	
Study model: Anti-cancer effects of resveratrol through immunomodulation (<i>in vitro</i> studies)			
Resveratrol: 20 μM for 48 hr	A549 & H1299 (Human lung cancer cell) HMDMs	Reduction of M2 polarization & activation	
		Decrease in TCM-stimulated IL-10 production and other M2 markers	
		Reduction of STAT3 phosphorylation	
		Enhancement of IL-12 and TNF-α secretion	
		↓ Tumor proliferation and invasion <i>in vitro/in vivo</i>	
Resveratrol: 5-50 μM for 24 hr	Human monocyte THP-1 cells, M2-polarized THP-1 macrophages, lymphatic endothelial cells (HLECs)	Decrease in of M2-polarized THP-1 macrophages	
		STAT3, IL-10 & MCP-1 inhibition	
		Reduction of VEGF- stimulated HLEC motility, invasion, and lymphangiogenesis	
		↓ Tumor invasion and angiogenesis <i>in vitro/in vivo</i>	

Continued Table 1.

Resveratrol: 25–50 μ M for 2 hr	Bone marrow-derived dendritic cells (BMDCs)	Downregulation of IFN- γ -mediated IDO expression and function Reduction of JAK/STAT and PKC δ -dependent mechanisms in BMDCs Elevation of CD8 $^{+}$ T cell polarization and CTL activity Suppression of tumor growth and IDO-mediated immune tolerance Reduction of the immunosuppressive functions of G-MDSCs through decreased ROS and Arg-1 levels Enhancing CTL activity	(83)
Resveratrol: 0- 100 μ mol/l for 6 and 12 hr	Myeloid-derived suppressor cells (MDSCs)	Stimulation of M-MDSC maturation Blocking HMGB1-induced immune suppression in MDSCs Significant inhibition of MDSC-mediated proliferation and tumor immune evasion	(87)
Resveratrol: 20 μ M, 100 μ M for 1-3 days	CD4 $^{+}$ T cells	Induction of TCR-dependent cell cycle progression at 20 μ M and 100 μ M Resveratrol acts as a strong activator of Sirt1 deacetylase Promotion of cell cycle arrest in the G1 phase (100 μ M) or G2 phase (20 μ M) in CD4 $^{+}$ T cells Activation of cell cycle arrest via p53 pathway (20 μ M) Stimulation of CD4 $^{+}$ T cell effector activity and IFN- γ production ↑ Anti-tumor immune response driven by CD4 $^{+}$ T cell Enhancement of NK cell cytotoxicity through Up-regulation of Akt-related transcription factors (e.g., c-Myb) in NK cells	(92)
Resveratrol: 20 μ M for 36 hr	Human NK cell line (NK92)	Increase in IL-2-Induced IFN- γ secretion from NK Cells Overexpression of NK cell-activating receptor CD107a ↑ IL-2 secretion in NK cells and inhibition of tumor growth	(52, 106)
Resveratrol: 12.5 μ M for 4 hr	NK92 cells, K562, HepG2, and A549 cells	Up-regulation of perforin expression and NK92 cell cytotoxicity via NKG2D-dependent ERK-1/2 and JNK-MAPK signaling pathways in cancer cells No observed effect on STAT3 or STAT5 protein expression Dose-dependent anti-tumor responses	(108)
4 – 32 μ mol/l for 24-72 hr	HL60 human leukemia cells, T47D breast carcinoma cells	Selective activation of the CD95 (FasL) pathway to induce apoptosis in cancer cells without affecting normal cells acts as both a chemopreventive and a chemotherapeutic agent through the CD95 pathway	(109)
Resveratrol: 0.6 – 10 μ g/mL for 18 hr to 6 days	PBMC	At low concentrations: enhanced the differentiation of CD8 $^{+}$ and CD4 $^{+}$ T cells into IL-2, IL-4, and IFN- γ producers after anti-CD3/anti-CD28 stimulation, and increased secretion of cytokines At higher concentrations, it suppressed cytokine production and T-cell proliferation cell activity increased at low concentrations and suppressed at higher concentrations dose-dependent immunomodulator, through cytokine production and T-cell proliferation	(110)
Resveratrol: 10 $^{-5}$ M to 3 $\times$ 10 $^{-3}$ M for 5 min to 2.5 hr	K562, PBMC	Platelet aggregation inhibition through downregulation of integrin gpIIb/IIIa expression on platelet surfaces Increased tumor cell susceptibility to NK cell-mediated cytotoxicity Reduction in TXA $_2$ production via inhibition of COX1-dependent pathways Increased NK cell-mediated cytotoxicity	(130)
Study model: Anti-cancer effects of resveratrol through immunomodulation (<i>in vivo</i> studies)			
100 mg/kg /day IP for 4 weeks	LLC tumor xenografts	Reduction of M2 polarization & activation Decrease in TCM-stimulated IL-10 production and other M2 markers Reduction of STAT3 phosphorylation Enhancement of IL-12 and TNF- α secretion ↓ Tumor proliferation and invasion <i>in vitro/in vivo</i>	(65)

Continued Table 1.

25 mg/kg twice daily, orally for 30 days	LM8-bearing mice	Decrease in of M2-polarized THP-1 macrophages	(74)
		STAT3, IL-10 & MCP-1 inhibition	
50 mg/kg every 2 days for 3 weeks	EG7 thymoma-bearing mice	Reduction of VEGF- stimulated HLEC motility, invasion, and lymphangiogenesis	(83)
		↓ Tumor invasion and angiogenesis <i>in vitro/in vivo</i>	
		Downregulation of IFN- γ -mediated IDO expression and function	
		Reduction of JAK/STAT and PKC δ -dependent mechanisms in BMDCs	
50 mg/kg /day for 3 weeks	LLC-bearing mice	Elevation of CD8 $^{+}$ T cell polarization and CTL activity	(87)
		Suppression of tumor growth and IDO-mediated immune tolerance	
		Reduction of the immunosuppressive functions of G-MDSCs through decreased ROS and Arg-1 levels	
		Enhancing CTL activity	
		Stimulation of M-MDSC maturation	
4 mg/kg IP (single dose)	EG7 tumor-bearing mice (T lymphoblast)	Blocking HMGB1-induced immune suppression in MDSCs	(97)
		Significant inhibition of MDSC-mediated proliferation and tumor immune evasion	
		Reduction in the Treg cell population	
		Suppressed secretion of TGF- β	
		Increased IFN- γ expression in CD8 $^{+}$ T cells	
Resveratrol (0.5 mg/kg) IV in the presence of IL-2	Murine models bearing B16F10 metastatic melanoma	↑ Anti-tumor immune response both <i>ex vivo</i> and <i>in vivo</i>	(52, 106)
		Enhancement of NK cell cytotoxicity through Up-regulation of Akt-related transcription factors (e.g., c-Myb) in NK cells	
		Increase in IL-2-Induced IFN- γ secretion from NK Cells	
		Overexpression of NK cell-activating receptor CD107a	
0.03% and 0.06% resveratrol	HFD-induced obese & diet-resistant mice	↑ IL-2 secretion in NK cells and inhibition of tumor growth	(124)
		Elevated numbers of Tregs (as negative regulators of inflammation)	
		Suppression of long-term oxidative stress and pro-inflammatory gene activity	
		Marked transition from Th1 to Th2 cytokine profiles	
< 5 mg/kg /day IP)	Renal tumor model	↓ Inflammation and oxidative stress	(131)
		Induction of CD8 $^{+}$ T cell-mediated anti-tumor immunity via increased MHC-I expression on APCs	
		Increased levels of Th1 cells and Th1-associated cytokines (IFN- γ)	
		Reduction in Th2-associated cytokines IL-6 and IL-10	
		Notable decrease in Tregs in the TME	
		Lower levels of the angiogenesis factor VEGF	
		↓ Tumor progression and angiogenesis	

MCP-1: Monocyte chemoattractant protein-1; HLECs: Human lymphatic endothelial cells; HMDMs: Human monocyte derived macrophage; LCC: Lewis lung cancer cell; IP: Intraperitoneal; BMDCs: Bone marrow-derived dendritic cells; IDO: Indoleamine 2,3-dioxygenase; PKC δ : Protein kinase C δ ; CTL: Cytotoxic T lymphocyte; G-MDSC: Granulocytic MDSCs; M-MDSC: Monocytic MDSC; LUAD: Lung adenocarcinoma; IV: Intravenously; MICA/B: Major histocompatibility complex class I chain-related proteins A and B; PBMC: Peripheral blood mononuclear cells

Interaction of resveratrol with TME immune cells

The modulatory effects of resveratrol on immune cells in the breast TME are shown in Figure 4, with Table 1 summarizing its immunological and anti-cancer effects across different experimental models. Also, Table 2 summarizes clinical studies on the anticancer and anti-inflammatory effects of resveratrol.

Tumor-associated macrophages

In the TME of a breast tumor, a type of immune cell called a tumor-associated macrophage (TAM) is the most

abundant. In over 80% of breast cancer cases, high levels of tumor-associated macrophages (TAMs) are associated with a worse prognosis (70). Resveratrol significantly reduces breast cancer cell growth in MDA-MB-231 and cisplatin-resistant MDA-MB-231 cell lines by modulating the M1/M2 macrophage polarization ratio, leading to overexpression of the C-X-C motif chemokine ligand 10 (CXCL10) gene, an M1 marker. This effect is enhanced by a strong inhibition of the IL-6/pSTAT3 pathway, suggesting a mechanism by which resveratrol modulates immune responses and tumor growth (71).

Table 2. Clinical studies about the anti-cancer and anti-inflammatory effects of resveratrol

Treatment	Type of study	Results	Ref.
5 g orally for 2.5 and 5 hr after overnight fasting	Randomized, single-dose pilot trial involving 10 healthy male volunteers	Substantial elevation of IDO activity Notable reduction of tryptophan levels Significant modulation of immune function Resveratrol was well tolerated with a favorable safety profile Marked increase in circulating $\gamma\delta$ T cells and Tregs	(84)
1000 mg/day for 28 days	Phase 1 randomized trial involving 9 healthy Japanese participants	Stable levels of CD8 ⁺ T cells, CD4 ⁺ T cells, and CD19 ⁺ B cells Lower plasma concentrations of the proinflammatory cytokines TNF- α and MCP-1 Significant increase in plasma anti-oxidant activity ↓ Inflammation and oxidative stress	(98)
5 or 50 mg of trans-resveratrol/ twice daily for 12 weeks	Randomized, double-blind, placebo-controlled clinical trial involving 39 adult women at increased risk of breast cancer	Reduction of RASSF-1 α methylation (key tumor suppressor gene) Reduction of PGE ₂ ; Resveratrol can induce RASSF-1 α demethylation and reduce inflammation	(132)

Tregs: Regulatory T cells; CD8⁺: Cluster of differentiation 8 positive; CD4⁺: Cluster of differentiation 4 positive; CD19⁺: Cluster of differentiation 19 positive; TNF- α : Tumor necrosis factor α , MCP-1: Monocyte chemoattractant protein-1; IDO: Indoleamine 2,3-dioxygenase; PGE₂: Prostaglandin E₂; RASSF-1 α : Ras association domain family member 1 α

Resveratrol may reduce the cancer-promoting activity of TAMs by blocking the NF- κ B pathway (72). A major factor in the metastasis of breast cancer to the lungs is the EMT, which TAMs trigger through changes in the JAK/STAT3 signaling pathway (73). Resveratrol (50 μ M) suppresses M2-polarized ToHoku Hospital Physician-1 (THP-1) macrophages, leading to reduced tumor invasion and angiogenesis by decreasing STAT3 activity, IL-10 secretion, and expression of monocyte chemoattractant protein-1 (MCP-1). It also diminishes the movement, infiltration, and network formation of human lymphatic endothelial cells (HLEC) driven by VEGF. *In vivo*, administering resveratrol (25 mg/kg twice daily) inhibits tumor growth and lung metastasis in mice with highly metastatic osteosarcoma (LM8). It reduces the area of lymphatic endothelial cells within the tumors (74).

In advanced-stage breast cancer, tumor cells use transforming growth factor β (TGF- β) to modify the TME and evade immune detection. The immunosuppressive effects of TGF- β reduce the effectiveness of immunotherapy, particularly ICIs (75, 76).

Resveratrol (0-100 μ M for 24 hr) can help by increasing the levels of macrophage inhibitory cytokine 1 (MIC-1), which is part of the TGF- β superfamily, in human pancreatic cancer cell lines (12). Although TGF- β promotes immune evasion, resveratrol increases MIC-1 protein expression (via p53), which promotes anti-cancer activity. This effect is linked to the tumor suppressor p53, which promotes MIC-1 expression. Consequently, it demonstrates both anti-cancer properties and potential as a diagnostic biomarker and treatment target (77, 78). Li *et al.* investigated the effects of a combination of three natural polyphenols, including resveratrol, curcumin, and quercetin (RCQ), in mice with 4T1 breast cancer. RCQ treatment showed a dual effect by reducing immunosuppressive cells (such as Th2 cells, M2 macrophages, and N2 neutrophils) and increasing CD4⁺ and CD8⁺ T cells, ultimately leading to enhanced cancer cell death via ROS-induced apoptosis (29).

Dendritic cells

DCs are known to exhibit immune-suppressive

characteristics, one of which is the expression of indoleamine 2,3-dioxygenase (IDO) (79). IDO is an enzyme that can inhibit T cell activation and promote immune tolerance. The overexpression of IDO creates a barrier to effective immunotherapy (77, 80). Recent studies have identified phytochemicals such as resveratrol as promising therapeutic agents that can target JAK/STAT signaling and modulate IDO expression in cancer cells, particularly in the breast TME (81, 82). Resveratrol modulates the immune response mediated by DCs by regulating IDO expression (83).

Resveratrol, at concentrations of 25-50 μ M, effectively inhibits the expression and function of IDO in bone marrow-derived dendritic cells (BMDCs) through JAK/STAT signaling and protein kinase C δ (PKC δ) mechanisms. This inhibition enhances anti-tumor responses by promoting CD8⁺ T cell polarization and increasing cytotoxic T lymphocyte (CTL) activity. *In vivo*, administration of resveratrol (50 mg/kg every 2 days for 3 weeks) has reduced tumor growth and modified IDO-mediated immune tolerance in mice with EG7 thymoma (83).

A pilot study with 10 healthy male participants evaluated the Kynurenine/ Tryptophan (Kyn/Trp) ratio as an indicator of IDO activity after administering 5 g of resveratrol. The results showed a significant reduction in tryptophan levels and a corresponding increase in IDO activity at 2.5 and 5 hr post-treatment compared to the placebo group. Despite the limited sample size, which characterizes this study as preliminary, the findings highlight resveratrol's effect on tryptophan metabolism, with implications for immune function, cancer progression, and cardiovascular health (84). In this study, resveratrol acutely increased IDO activity in healthy humans as an anti-inflammatory measure. Still, in long-term studies of cancer models, resveratrol inhibited IDO expression, thereby reversing immunosuppression and restoring anti-tumor immunity.

Myeloid-derived suppressor

Today, researchers are interested in how myeloid-derived suppressor cells (MDSCs) can promote tolerance in cancer, particularly regarding their contribution to peripheral tolerance in breast cancer (85, 86).

In vitro studies show that resveratrol induces apoptosis in granulocytic MDSCs (G-MDSCs). Resveratrol may reduce their immunosuppressive effects by decreasing ROS and Arg-1 levels while enhancing CTL activity. *In vivo*, administration of resveratrol (50 mg/kg daily for 3 weeks) has decreased G-MDSCs levels and promoted the expansion of CD8⁺ IFN- γ ⁺ cells in mice with LLC tumors (87). Resveratrol has promoted the maturation of monocytic-MDSCs (M-MDSC) into CD11c⁺ and F4/80⁺ cells *in vitro*, but did not significantly alter M-MDSC levels in living organisms after treatment (87). Notably, the reduction in MDSC accumulation appears linked to lower HMGB1 levels after resveratrol treatment, highlighting the crucial role of HMGB1 in MDSC growth and tumor evasion (87, 88).

T lymphocytes

Resveratrol is being explored as a potential adjunct therapy for lung metastasis in TNBC due to its ability to enhance local anti-tumor immune responses. It promotes the activation of CD8⁺ T cells and increases the production of IFN- γ and IL-2 (89). Furthermore, resveratrol treatment (12.5 or 25 mg/kg for 21 days) improved CD8⁺ T cell cytotoxicity and Th1 responses while reducing PD-1 expression on pulmonary CD8⁺ and CD4⁺ T cells. This intervention reduced lung metastasis in TNBC by decreasing PD-1 levels and polarizing macrophages toward the M1 phenotype in tumor-bearing mice (90).

Sirtuins (SIRT), classified as Class III histone deacetylases, are NAD⁺-dependent enzymes that are critically involved in regulating cellular metabolism. SIRTs manage cellular responses to stress and play a crucial role in T cell metabolism and functions (91).

Craveiro *et al.* show that both low (20 μ M) and high (100 μ M) doses of resveratrol influence the cell cycle progression of T-cell receptor-stimulated CD4⁺ T cells, leading to different types of cell cycle arrest. At low doses, resveratrol enhances IFN- γ secretion by activating SIRT1 deacetylase. This induces genotoxic stress and DNA damage, which subsequently activate p53 in CD4⁺ T cells. Conversely, high concentrations disrupt antigen receptor signaling and cause cell cycle arrest in the G₁ phase. In contrast, the low-dose genotoxic stress response connects metabolic reprogramming to improved CD4⁺ T cell effector function (92).

According to Yang *et al.*, resveratrol at concentrations under five μ M suppresses anti-tumor immunity through PD-L1 modulation and the Wnt signaling pathway. Resveratrol activates SIRT1 which promotes the deacetylation and stabilization of Snail. This process represses Axin2 transcription, thereby increasing the binding of the β -catenin/TCF complex to the PD-L1 promoter in lung adenocarcinoma cells. Conversely, higher resveratrol concentrations (>40 μ M) lead to a gradual decrease in PD-L1 expression (93).

SIRT2 may help attract different T cell types, such as CD8⁺ and CD4⁺ T cells, regulatory T cells (T_{regs}), and NK cells, and its expression is positively linked to PD-1 levels (91, 94). Triacetyl-resveratrol, a resveratrol analog, is the most effective activator of SIRT2, with an EC₅₀ of 142.79 nM (94). This indicates its potential as an immunomodulatory agent that could improve overall survival in lung adenocarcinoma patients when combined with anti-PD-1 therapy (94, 95). A negative correlation between increased T_{reg} numbers in the

TME and patient survival outcomes has been established (96). A single intraperitoneal dose of resveratrol (4 mg/kg) in tumor-bearing mice reduced T_{regs} and TGF- β secretion while increasing IFN- γ expression in CD8⁺ T cells. These findings suggest that resveratrol could serve as a beneficial adjunct therapy to enhance the anti-tumor immune response (97). It was reported that resveratrol-based compounds could influence immune responses by regulating lymphocyte expansion and T_{reg} dynamics in breast cancer models (21).

A pilot randomized trial investigated the immunomodulatory effects of resveratrol in nine healthy Japanese participants, administering 1000 mg/day for 28 days. The study found that resveratrol was safe and well-tolerated, significantly increasing gamma delta ($\gamma\delta$) T cells and Tregs, while minimally affecting CD8⁺ T cells, CD4⁺ T cells, and CD19⁺ B cells. Additionally, compared with both baseline levels and control participants, plasma TNF- α and MCP-1 levels decreased significantly, while plasma antioxidant activity increased significantly (98).

In another study, resveratrol was shown to reduce oxidative stress, decrease pro-inflammatory gene expression, and increase T_{reg} numbers, which help regulate inflammation. Furthermore, the study highlighted a notable shift in cytokine production from a Th1 profile (TNF- α) to a Th2 profile (IL-10) in the splenocytes of mice (99).

The increase of PD-L1 in the TME, upregulated by T_{regs} and cancer cells, causes CTLs to become exhausted. Research shows that resveratrol can block the effects of PD-L1 on CTLs, helping to maintain anti-tumor immunity (100). Overall, resveratrol influences T-cell activation in distinct mechanisms. It suppresses CD4⁺ T-cell activation and diminishes the inhibitory role of T_{regs} that serve to control tumor growth (101).

Tumor-evoked B_{regs} (tB_{reg})

To effectively block lung metastasis in breast cancer, it is essential to regulate T_{regs} and tB_{reg} (Tumor-evoked B_{regs}) (102). Resveratrol, administered intraperitoneally at 50 μ g/mouse, has been shown to prevent breast cancer progression and metastasis by STAT3 and tB_{reg} suppression. Furthermore, by reducing TGF- β production, it prevents the conversion of tB_{reg} to T_{regs}, without influencing MDSC populations in 4T1-tumor-bearing mice (103).

Additionally, resveratrol targets PPAR- α , a nuclear receptor involved in various cellular processes, to prevent cancer cells from converting B cells into tB_{reg}. Blocking tB_{reg} suppressed T-cell proliferation, tumor progression, and lung metastasis. This intervention highlights the critical role of PPAR- α in the generation of tB_{reg} (104).

Natural killer cells

Resveratrol is emerging as a promising adjuvant in cancer immunotherapy due to its ability to enhance NK cell activity (52). It has dual effects; low doses activate NK cells, while high doses induce apoptosis through the caspase signaling pathway (105). A combination of resveratrol (20 μ M) with IL-2 (5 ng/ml) significantly boosts NK cell cytotoxicity, increases IFN- γ secretion, and activates receptor expression. This effect is mediated by the activation of cellular Myeloblastosis viral oncogene homolog (c-Myb), a key transcription factor for NK cell activation (52). In an *in vivo* study in mice with B16F10 metastatic melanoma, a combination of intravenous resveratrol (0.5 mg/kg) and IL-2 resulted in a notable reduction in tumor growth and




Figure 5. Dual strategies of resveratrol to enhance immunity and combat tumors via PD-1/PD-L1 regulation

(A) Enhanced immune cell activation: Resveratrol activates CTLs, critical effectors in breast tumor immunity, by upregulating MHC-I on DCs, thereby enhancing tumor cell recognition and targeting. (B & C) Immune checkpoint inhibition. Resveratrol functions as an ICI by counteracting PD-1 overexpression-mediated immunosuppression in cold tumors. It reduces the interaction between PD-1 and its ligand, PD-L1, on tumor cells, preventing T cell exhaustion. Conversely, in hot tumors, which exhibit high immune activity, resveratrol lowers PD-L1 expression, thus enhancing CTL activation and their anti-tumor effectiveness. (D) Tumor cell viability and proliferation. Resveratrol interferes with tumor cell viability by targeting glyco-PD-L1 processing enzymes, thereby affecting PD-L1 maturation, which contributes to tumor resistance to immune attack. (E) Apoptosis promotion: In addition to rendering cancer cells more susceptible to apoptosis, resveratrol directly modulates apoptotic signaling pathways.

metastasis compared with IL-2 alone (106).

Pan *et al.* conducted research on various breast cancer cell lines, treating them with resveratrol at 6.25 μ M and 25 μ M for 48 hr. They also administered resveratrol intraperitoneally to BCap37 tumor-bearing mice at doses of 0, 25, or 100 mg/kg/day for 28 days. The findings indicated that resveratrol significantly reduced the inhibitory effects of miR-17 on MHC class I polypeptide-related sequence A and B (MICA and MICB). This potentially enhances the cytotoxic activity of NK cells and suggests a promising therapeutic approach to improve anti-tumor immunity in breast cancer patients (107).

Humans express eight cell surface glycoproteins that act as ligands for natural killer group 2 member D (NKG2D), an activating receptor on NK cells. At a concentration of 12.5 μ M, resveratrol significantly enhances the cytotoxic activity of NK cells, primarily via NKG2D-mediated ERK-1/2 and JNK-MAPK signaling pathways. Additionally, it promotes Up-regulation of perforin expression without affecting STAT3 and STAT5 protein expression levels in myeloid leukemia (K562), hepatocellular carcinoma (HepG2), and human lung adenocarcinoma (A549) cell lines (108). Resveratrol (32 μ mol/l) has been shown to uniquely boost the Factor Associated with Suicide ligand (FasL) expression on human leukemia cells and breast carcinoma cells, enabling NK cells to induce apoptosis through signaling pathways (109).

Falchetti *et al.* found that low concentrations of resveratrol (up to 0.3 μ g/ml) enhanced the cytotoxic activity of NK cells, whereas higher concentrations (5 and 20 μ g/ml) significantly reduced it. Additionally, when peripheral blood mononuclear cells were stimulated with anti-CD3/anti-CD28 antibodies, low resveratrol concentrations (0.625-2.5 μ g/ml) increased the frequency of CD8⁺ T cells that produced IFN- γ , IL-2, and IL-4, and CD4⁺ T cells that produced IFN- γ . However, the highest concentration of resveratrol (10 μ g/ml) suppressed cytokine production (110). Resveratrol enhances the cytotoxic activity of NK cells against myeloid leukemia tumor cells, thereby increasing

their susceptibility to NK cell-mediated cytotoxicity.

In summary, resveratrol shows promise as an adjuvant in cancer immunotherapy due to its ability to modulate NK cell activity. At low doses, it enhances NK cell activation, while at higher concentrations, it can induce apoptosis in NK cells. Research indicates that combining resveratrol with IL-2 boosts NK cell cytotoxicity and cytokine secretion, resulting in reduced tumor growth and metastasis. Additionally, resveratrol inhibits miR-17 expression and enhances NKG2D signaling, thereby improving anti-tumor immunity. However, its effects are concentration-dependent, as high doses may suppress NK cell function.

Dual effects of resveratrol on PD1/PD-L1 pathway

Resveratrol may enhance the effectiveness of immunotherapy by converting “cold” tumors into “hot” ones via mechanisms involving the PD-1/PD-L1 pathway (Figure 5, Table 3). Resveratrol has demonstrated pleiotropic effects on immune response. The effect of resveratrol on PD-L1 expression varies with cancer type, exposure duration, and concentration. An initial cellular stress response might activate pathways like NF- κ B, leading to Up-regulation of PD-L1. With prolonged exposure, direct inhibitory mechanisms, such as the disruption of PD-L1 glycosylation and stability, may dominate, leading to a net reduction in functional PD-L1 on the cell surface (111).

Evidence from animal models suggests that combining resveratrol with immunotherapy strategies, such as intravenous immunocytokine (112) and/or ICIs, leads to better tumor control and longer survival than either treatment alone (21, 111).

Up-regulation of PD-L1

Resveratrol and one of its metabolites, piceatannol (3',4',3,5-*trans*-trihydroxystilbene), can increase PD-L1 levels in the human TNBC cell line (Cal51) and colon cancer cells (SW620). In addition, the synergistic effect of resveratrol and piceatannol reduces tumor cell viability. This effect was marked by increased DNA damage signals and

Table 3. Different effects of resveratrol in immunotherapy through PD1/PD-L1 pathway

Mechanism of action	Study model	Findings of study	Resveratrol's effect on immunotherapy
Inhibits Glyco-PD-L1	<i>In vitro</i> basal-like/HER2+ breast cancer cells	↑ Cytotoxic T-lymphocyte immune-surveillance in TME of breast tumor	Resveratrol makes tumors more vulnerable to immune attack
		De-localization of PD-L1 through disruption in N-glycan branching	
		PD-L1 maturation disruption (99)	
PD-L1 Up-regulation	<i>In vitro</i> Cal51 triple-negative breast cancer	↑ level of PD-L1	Resveratrol behaves like radiotherapy through stress response induction in tumors, making the tumor more visible to the immune system
		↓ Tumor cell survival	
		↑ DNA-damaging marker	
Lowers PD-L1 expression	<i>In vitro</i> A549 and H1299 (Human lung adenocarcinoma)	Activation of caspase-3	Resveratrol decreases immune exhaustion
		Inhibition of p38-MAPK/c-Myc pathways (112)	
		Dose-dependently upregulates PD-L1 expression through snail-driven activation of the Wnt pathway (92)	
PD-L1 inhibition	<i>In vitro</i> Human oral epidermoid carcinoma cell line	Resveratrol inhibits thyroxine related PD-L1 accumulation in cancer cells	Resveratrol prevents immune resistance
		Removes "off switch" signal (132)	
		↑ Anti-tumor activity of CD8 ⁺ T cells	
PD-L1 inhibition	<i>In vitro</i> Cancer stem-like cells in oral cancer cells	↓ PD-1 expression on CD8 ⁺ & CD4 ⁺ T cells	Resveratrol improves immunotherapy efficacy through PD-L1 inhibition
		↑ Macrophages to M1 phenotype (89)	
		Nano-formulated resveratrol inhibited PD-L1 through IL-6/JAK2/STAT3 axis (133)	
PD-L1 inhibition	<i>In vitro</i> pair ELISA & surface plasmon resonance	Inhibition of PD-1/PD-L1	
		Selectively bind to PD-L1 (114)	

PD-L1: Programmed death-ligand 1; HER2: Human epidermal growth factor receptor 2; TME: Tumor microenvironment; MAPK: Mitogen-activated protein kinase; c-Myc: Cellular myelocytomatosis; Wnt: Wingless-related integration site; IL-6: Interleukin 6; JAK2: Janus kinase 2; STAT3: Signal transducer and activator of transcription 3; ELISA: Enzyme-linked immunosorbent assay; PD-1: Programmed cell death protein 1; TNBC: Triple-negative breast cancer; DNA: Deoxyribonucleic acid; CD8: Cluster of differentiation 8; CD4: Cluster of Differentiation 4

caspase-3 activation via suppression of p38-MAPK/c-Myc. This research suggests that the combination of resveratrol and piceatannol, along with anti-PD-L1 immunotherapy, could be beneficial for breast cancer patients with low or no PD-L1 levels (113).

In a study by Hsieh and Wu, the synergistic effects of resveratrol and piceatannol on PD-L1 overexpression were investigated. Their combination strategy enhances the efficacy of anti-PD-1/PD-L1 immune checkpoint blockade. The goal is to enhance the detection and destruction of cold tumors with low PD-L1 expression by targeting and eliminating them via the host anti-tumor immune mechanisms (114).

Inhibition of PD-L1

Verdura *et al.* introduced a novel approach using resveratrol to combat aggressive breast cancer by targeting PD-L1 in HER2+ cells. Resveratrol directly inhibits glyco-PD-L1 processing enzymes, leading to a build-up of the abnormal glycosylated form of PD-L1. It also prevented PD-L1/PD-1 interaction and reduced PD-L1 expression on the cell surface (100). This is a direct, post-translational

mechanism for downregulating functional PD-L1, thereby acting as a natural checkpoint inhibitor.

In another study, Li *et al.* conducted additional investigations into the inhibitory effects and binding capabilities of natural compounds, including resveratrol, on PD-L1. This study used a combination of two tests, including i) measuring the ability to block PD-1/PD-L1 interaction and ii) measuring the binding of compounds to PD-1 and PD-L1. The compounds were classified into four groups: PD-1/PD-L1 inhibitors, selective PD-L1 inhibitors, non-binding PD-1/PD-L1 inhibitors, and non-inhibiting PD-1/PD-L1 binders. Resveratrol is a PD-1/PD-L1 inhibitor that selectively binds to the PD-L1 protein (115). In conclusion, resveratrol functions as a multi-target agent that bridges oncogenic and immunomodulatory pathways. Its paradoxical effects on PD-L1 emphasize its biological complexity.

Challenges and future directions

In vivo and *in vitro* studies have demonstrated the anti-inflammatory and immunomodulatory effects of resveratrol; however, translating these findings into clinically significant outcomes in breast cancer treatment remains challenging

(116). The most commonly administered dose of resveratrol in clinical trials is 500 mg, followed by 1 g daily. Resveratrol is usually well-tolerated at daily doses of up to 1 g (117). It is essential to conduct a specialized, well-designed, double-blinded randomized trial (117, 118). These trials should measure appropriate biomarkers, such as serum cytokine levels, immune cell subsets, or gene expression profiles, to accurately assess immune responses (99).

One of the major challenges in using resveratrol in cancer immunotherapy is the influence of the gut microbiota on its metabolism and efficacy. Studies have shown that microbiota can significantly affect the efficacy of the PD-L1/PD-1 pathway (119) and the biological activity of resveratrol (120). This can lead to variations in resveratrol efficacy for treating breast cancer among different patients. Resveratrol, in combination with an anti-PD-1 monoclonal antibody, enhances anti-tumor effects via the gut microbiome and increases the abundance of *Desulfovibrio fairfieldensis*. Notably, prostaglandin D2 acts as a key mediator of this process by promoting CD8⁺ T cell infiltration into tumor tissue (121).

Resveratrol is generally well-tolerated (122), but may cause nephrotoxicity, gastrointestinal issues, and hypersensitivity reactions in some individuals (123). Its efficacy depends on dosage: low concentrations confer antioxidant benefits for cancer prevention (124), whereas high doses may induce DNA damage and oxidative stress due to pro-oxidant activity (123). The *in vivo* pharmacokinetics of resveratrol is challenged by low bioavailability, metabolic turnover, and complex metabolic pathways, including phase II hepatic detoxification and intestinal bacterial metabolism (123). Also, resveratrol stability is influenced by factors such as UV radiation, pH, and temperature (42). To optimize the therapeutic benefits of resveratrol, it is necessary to enhance its poor bioavailability and stability by developing advanced delivery systems (e.g., liposomes, cyclodextrins, solid lipid nanoparticles) and synthesizing resveratrol derivatives (125, 126). Collaborations among researchers, industry experts, and regulatory agencies are crucial for the development of advanced resveratrol-based delivery systems for clinical applications.

Conclusion

Based on the presence of TILs, tumors are classified as “hot” or “cold”. A significant challenge in oncology is converting cold tumors into hot ones, thereby sensitizing them to immunotherapy. This transformation requires a multi-faceted approach targeting key mechanisms within TME. The complex interactions between immune cells and the breast cancer TME are pivotal in disease progression and resistance to immunotherapy. The inhibitory effect of resveratrol on key oncogenic pathways (PI3K/Akt/mTOR, MAPK/ERK, STAT, NF- κ B, and β -catenin) not only reduces cancer cell proliferation and survival but also fundamentally reprograms the TME to facilitate immune attack. Resveratrol promotes the conversion of immunologically “cold” breast tumors to “hot” tumors through the synergistic integration of three mechanisms, i.e., immune reprogramming, oncogenic signaling disruption, and checkpoint blockade, which collectively remodel the TME.

The first aspect is the effects of resveratrol on oncogenic pathways. It inhibits the PI3K/Akt/mTOR pathway by

reducing Akt phosphorylation and the activity of its downstream target mTOR, and it blocks NF- κ B activation. This inhibition decreases cancer cell proliferation and promotes apoptosis. Additionally, resveratrol modulates the MAPK/ERK pathway by reducing ERK phosphorylation, thereby decreasing cancer cell survival and stimulating apoptosis. By blocking STAT phosphorylation and NF- κ B activation, resveratrol prevents the nuclear translocation of STATs and the expression of pro-oncogenic genes. Therefore, invasion, migration, and metastasis of cancer cells are significantly reduced. Furthermore, resveratrol inhibits the accumulation of β -catenin in the cytoplasm, which prevents its nuclear translocation. This disruption suppresses transcription of target genes critical for cell proliferation, survival, and metastasis.

The second aspect concerns resveratrol's effect on immunomodulatory cells. Resveratrol has the potential to activate immunostimulatory cells, including M1-TAMs, N1-TANs, DCs, NKs, CTLs, and Th1. This activation boosts anti-tumor immunity through increased cytokine production, antigen presentation, and cytotoxicity. Simultaneously, resveratrol inhibits the function of immunosuppressive cells that support tumor progression, including tBregs, Tregs, Th2 cells, MDSCs, M2-TAMs, and N2-TANs.

The third aspect is the dual effects of resveratrol on PD1/PD-L1 pathway. Resveratrol combats tumors through a dual strategy focused on the PD-1/PD-L1 immune checkpoint. It enhances immunity by activating CD8⁺ cytotoxic T cells (CTLs) through improved antigen presentation on DCs. Concurrently, it acts as a natural immune checkpoint inhibitor. In cold tumors, it blocks the PD-1/PD-L1 interaction to prevent T-cell exhaustion, whereas in hot tumors, it directly downregulates PD-L1 expression on cancer cells to enhance CTL attack.

Furthermore, resveratrol damages tumor defenses by inhibiting PD-L1 maturation and inducing apoptosis in cancer cells. Beneficial effects include inhibiting PD-L1 expression on tumor cells, reducing PD-1 expression on T cells, enhancing CD8⁺ T cell infiltration, and suppressing EMT. In some studies, resveratrol upregulated PD-L1 expression but still decreased tumor cell survival. It seems that in these cases, resveratrol behaves like radiotherapy, inducing a stress response in tumors that makes them more visible to the immune system.

However, its effectiveness is limited due to poor bioavailability, and the biological activity of its metabolites differs. Future clinical trials are essential to validate these findings, assess safety, and optimize therapeutic protocols in breast cancer treatment. Such advancements could ultimately expand the arsenal against breast cancer, offering patients more effective and personalized therapeutic options.

Acknowledgment

The author expresses gratitude to Mashhad University of Medical Sciences, Iran, for their support in preparing this article.

Funding

The authors declare that no financial support was received for the research, authorship, and/or publication of this article.

Authors' Contributions

N A was responsible for conceptualization, data curation, investigation, validation, visualization, and both the original draft writing and the review and editing. B H managed supervision, validation, review, and editing. F M and MB assisted with supervision, validation, and review and editing.

Conflicts of Interest

The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Declaration

We have not used any AI tools or technologies to prepare this manuscript.

References

- Chen Y, Sun J, Luo Y, Liu J, Wang X, Feng R, *et al.* Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer. *J Transl Med* 2022;20:615.
- Rajabi S, Shakib H, Safari-Alighiarloo N, Maresca M, Hamzeloo-Moghadam M. Targeting autophagy for breast cancer prevention and therapy: From classical methods to phytochemical agents. *Iran J Basic Med Sci.* 2024;27:1475.
- Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. *Ann N Y Acad Sci* 2011;1215:1-8.
- Sadeghi M, Dehnavi S, Sharifat M, Amiri AM, Khodadadi A. Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME). *Heliyon* 2024; 10:e27480.
- Eftekhari R, Esmaeili R, Mirzaei R, Bidad K, de Lima S, Ajami M, *et al.* Study of the tumor microenvironment during breast cancer progression. *Cancer Cell Int* 2017;17:1-10.
- Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. *Cancer Res* 2019;79:4557-4566.
- Lan H-R, Du W-L, Liu Y, Mao C-S, Jin K-T, Yang X. Role of immune regulatory cells in breast cancer: Foe or friend? *Int Immunopharmacol* 2021;96:107627.
- Liu W, Kuang T, Liu L, Deng W. The role of innate immune cells in the colorectal cancer tumor microenvironment and advances in anti-tumor therapy research. *Front Immunol* 2024;15:1407449.
- Lei X, Lei Y, Li J-K, Du W-X, Li R-G, Yang J, *et al.* Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. *Cancer Lett* 2020;470:126-133.
- Moeinzadeh L, Mahmoudian-Sani M-R, Purrahan D, Azghadi F, Darbandi MA. Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer. *Iran J Basic Med Sci* 2025;28:1620.
- Chen Y, Yu D, Qian H, Shi Y, Tao Z. CD8+ T cell-based cancer immunotherapy. *J Transl Med* 2024;22:394.
- Mu Q, Najafi M. Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells. *Int Immunopharmacol* 2021;98:107895.
- Parvez A, Choudhary F, Mudgal P, Khan R, Qureshi KA, Farooqi H, Aspatwar A. PD-1 and PD-L1: Architects of immune symphony and immunotherapy breakthroughs in cancer treatment. *Front Immunol* 2023;14:1296341.
- Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi MH, Khorramdelazad H, Safari E, Farahmand L. Breast cancer immunotherapy: Current and novel approaches. *Int Immunopharmacol* 2021;98:107886.
- Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, *et al.* The immunology of hormone receptor positive breast cancer. *Front Immunol* 2021;12:674192.
- André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, *et al.* Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med.* 2019;380:1929-1940.
- Pu Z, Wang TB, Mou L. Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights. *Front Immunol* 2023;14:1310285.
- Yu W-D, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. *Cancer Lett* 2019;452:66-70.
- Kang Q, He L, Zhang Y, Zhong Z, Tan W. Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions. *Phytomedicine* 2024;155684.
- Chen L, Musa AE. Boosting immune system against cancer by resveratrol. *Phytother Res* 2021;35:5514-5526.
- Alqathama A. Natural products as promising modulators of breast cancer immunotherapy. *Front Immunol* 2024;15:1410300.
- Zhang W, Li S, Li C, Li T, Huang Y. Remodeling tumor microenvironment with natural products to overcome drug resistance. *Front Immunol* 2022;13:1051998.
- Messeha SS, Zarmouh NO, Soliman KF. Polyphenols modulating effects of PD-L1/PD-1 checkpoint and EMT-mediated PD-L1 overexpression in breast cancer. *Nutrients* 2021;13:1718.
- Shahrokhi H, Asili J, Tayarani-Najaran Z, Boozari M. Signaling pathways behind the biological effects of tanshinone IIA for the prevention of cancer and cardiovascular diseases. *Naunyn-Schmiedeberg's Archives of Pharmacology.* 2025;398:7877-7902.
- Venkat R, Verma E, Daimary UD, Kumar A, Girisa S, Dutta U, *et al.* The journey of resveratrol from vineyards to clinics. *Cancer Invest* 2023;41:183-220.
- Chhabra G, Singh CK, Amiri D, Akula N, Ahmad N. Recent advancements on immunomodulatory mechanisms of resveratrol in tumor microenvironment. *Molecules* 2021;26:1343.
- Trung LQ, An DTT. Is resveratrol a cancer immunomodulatory molecule? *Front Pharmacol* 2018;9:1255.
- Shi X-P, Miao S, Wu Y, Zhang W, Zhang X-F, Ma H-Z, *et al.* Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features. *Int J Mol Sci.* 2013;14:15655-15668.
- Li C, Xu Y, Zhang J, Zhang Y, He W, Ju J, *et al.* The effect of resveratrol, curcumin and quercetin combination on immunosuppression of tumor microenvironment for breast tumor-bearing mice. *Sci Rep* 2023;13:13278.
- Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, *et al.* Anti-tumor and immunomodulatory activity of resveratrol *in vitro* and its potential for combining with cancer immunotherapy. *Int Immunopharmacol* 2011;11:1877-1886.
- Burguin A, Diorio C, Durocher F. Breast cancer treatments: Updates and new challenges. *J Pers Med* 2021;11:808.
- Mantooth SM, Abdou Y, Saez-Ibañez AR, Upadhaya S, Zaharoff DA. Intratumoral delivery of immunotherapy to treat breast cancer: Current development in clinical and preclinical studies. *Front Immunol* 2024;15:1385484.
- Planes-Laine G, Rochigneux P, Bertucci F, Chrétien A-S, Viens P, Sabatier R, Gonçalves A. PD-1/PD-L1 targeting in breast cancer: The first clinical evidences are emerging—a literature review. *Cancers* 2019;11:1033.
- Setordzi P, Chang X, Liu Z, Wu Y, Zuo D. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. *Eur J Pharmacol* 2021;895:173867.
- Bullock KK, Richmond A. Beyond anti-PD-1/PD-L1: improving immune checkpoint inhibitor responses in triple-negative breast cancer. *Cancers.* 2024;16:2189.
- Adams S, Loi S, Toppmeyer D, Cescon D, De Laurentiis M, Nanda R, *et al.* Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. *Ann Oncol* 2019;30:405-11.
- Wu D, Tang S, Ye R, Li D, Gu D, Chen R, *et al.* Case Report: Long-term response to Pembrolizumab Combined with endocrine therapy in metastatic breast cancer patients with hormone receptor

- expression. *Front Immunol* 2021;12:610149.
38. Balibegloo M, Nejadghaderi SA, Sadeghalvad M, Soleymantabar A, Nezamabadi SS, Saghazadeh A, Rezaei N. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. *Int Immunopharmacol* 2021;96:107796.
 39. Zhao Q, Zhang J, Xu L, Yang H, Liang N, Zhang L, et al. Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: A systemic review and meta-analysis. *Front Immunol* 2021;12:730320.
 40. Su X, Li J, Xu X, Ye Y, Wang C, Pang G, et al. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy. *J Transl Med* 2024;22:751.
 41. Olagunju A, Forsman T, Ward RC. An update on the use of cryoablation and immunotherapy for breast cancer. *Frontiers in Immunology* 2022;13:1026475.
 42. Wang X, Wang L, Fekrazad R, Zhang L, Jiang X, He G, Wen X. Polyphenolic natural products as photosensitizers for antimicrobial photodynamic therapy: Recent advances and future prospects. *Front Immunol* 2023;14:1275859.
 43. Meyer C, Brockmueller A, Buhrmann C, Shakibaei M. Prevention and co-management of breast cancer-related osteoporosis using resveratrol. *Nutrients* 2024;16:708.
 44. Zhang L-X, Li C-X, Kakar MU, Khan MS, Wu P-F, Amir RM, et al. Resveratrol (RV): A pharmacological review and call for further research. *Biomed Pharmacother* 2021;143:112164.
 45. Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, et al. The role of resveratrol in cancer therapy. *Int J Mol Sci* 2017;18:2589.
 46. Rahbardi MG, Sahebkar A. Resveratrol as a naturally occurring inflammasome modulator: Implications for health and disease. *Iran J Basic Med Sci* 2025;28:1301.
 47. Sumimoto H, Takano A, Teramoto K, Daigo Y. RAS-mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers. *PLoS One* 2016;11:e0166626.
 48. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. *Cancer Treat Rev* 2013;39:935-946.
 49. Xing S, Chen S, Yang X, Huang W. Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells. *J BUON* 2020;25:1875-1882.
 50. Maharati A, Moghbeli M. Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF- β , and MAPK signaling pathways during breast tumor progression. *J Transl Med* 2023;21:556.
 51. Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. *Clin Cancer Res*. 2016;22:1499-1509.
 52. Lee Y-J, Kim J. Resveratrol activates natural killer cells through Akt-and mTORC2-mediated c-Myb Up-regulation. *Int J Mol Sci* 2020;21:9575.
 53. Chen H, Jin Z-L, Xu H. MEK/ERK signaling pathway in apoptosis of SW620 cell line and inhibition effect of resveratrol. *Asian Pac J Trop Med* 2016;9:49-53.
 54. Boozari M, Hosseinzadeh H. Crocin molecular signaling pathways at a glance: A comprehensive review. *Phytother Res* 2022;36:3859-84.
 55. Cetintas VB, Batada NN. Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment? *J Transl Med* 2020;18:45.
 56. Li X, Xiang Y, Li F, Yin C, Li B, Ke X. WNT/ β -catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment. *Front Immunol* 2019;10:2293.
 57. Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y, et al. Wnt/ β -catenin signaling pathway in carcinogenesis and cancer therapy. *J Hematol Oncol* 2024;17:46.
 58. Boozari M, Ebrahimi SN, Soltani S, Tayarani-Najaran Z, Emami SA, Asili J, Iranshahi M. Absolute configuration and anti-cancer effect of prenylated flavonoids and flavonostilbenes from *Sophora pachycarpa*: Possible involvement of Wnt signaling pathway. *Bioorganic Chemistry* 2019;85:498-504.
 59. Tsai J-H, Hsu L-S, Lin C-L, Hong H-M, Pan M-H, Way T-D, Chen W-J. 3, 5, 4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/ β -catenin signaling cascades and reversal of epithelial-mesenchymal transition. *Toxicol Appl Pharmacol* 2013;272:746-756.
 60. Lee HS, Ha AW, Kim WK. Effect of resveratrol on the metastasis of 4T1 mouse breast cancer cells *in vitro* and *in vivo*. *Nutr Res Pract* 2012;6:294-300.
 61. Jin W. Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial-mesenchymal transition. *Cells* 2020;9:217.
 62. Manore SG, Doheny DL, Wong GL, Lo H-W. IL-6/JAK/STAT3 signaling in breast cancer metastasis: Biology and treatment. *Front Oncol* 2022;12:866014.
 63. Wang Y, Zhang X, Xie X, Chen W, Li M, Diao D, Dang C. Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan. *Cancer Biol Ther* 2020;21:1179-1190.
 64. Ma C, Wang Y, Dong L, Li M, Cai W. Anti-inflammatory effect of resveratrol through the suppression of NF- κ B and JAK/STAT signaling pathways. *Acta Biochim Biophys Sin*. 2015;47:207-213.
 65. Sun L, Chen B, Jiang R, Li J, Wang B. Resveratrol inhibits lung cancer growth by suppressing M2-like polarization of tumor associated macrophages. *Cell Immunol* 2017;311:86-93.
 66. Pavitra E, Kancharla J, Gupta VK, Prasad K, Sung JY, Kim J, et al. The role of NF- κ B in breast cancer initiation, growth, metastasis, and resistance to chemotherapy. *Biomed Pharmacother* 2023;163:114822.
 67. Cao Y, Yi Y, Han C, Shi B. NF- κ B signaling pathway in tumor microenvironment. *Frontiers in Immunology* 2024;15:1476030.
 68. Csaki C, Mobasher A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: Inhibition of IL-1 β -induced NF- κ B-mediated inflammation and apoptosis. *Arthritis Res Ther* 2009;11:1-17.
 69. Chen M, Pockaj B, Andreozzi M, Barrett MT, Krishna S, Eaton S, et al. JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer. *Clin Breast Cancer* 2018;18:e1205-e1215.
 70. Li Y, Ganesan K, Chen J. Role of biological mediators of tumor-associated macrophages in breast cancer progression. *Curr Med Chem* 2022;29:5420-5440.
 71. Cheuk I, Chen J, Siu M, Ho J, Lam S, Shin VY, Kwong A. Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast cancer. *Clin Transl Oncol* 2022;1-10.
 72. Malla R, Padmaraju V, Kundrapu DB. Tumor-associated macrophages: Potential target of natural compounds for management of breast cancer. *Life Sci* 2022;301:120572.
 73. Qi Y, Li R, Han M. Tumor-associated macrophages induce epithelial-mesenchymal transition and promote lung metastasis in breast cancer by activating the IL-6/STAT3/TGM2 axis. *Int Immunopharmacol* 2024;143:113387.
 74. Kimura Y, Sumiyoshi M. Resveratrol prevents tumor growth and metastasis by inhibiting lymphangiogenesis and M2 macrophage activation and differentiation in tumor-associated macrophages. *Nutr Cancer* 2016;68:667-678.
 75. Yi M, Li T, Niu M, Wu Y, Zhao Z, Wu K. TGF- β : A novel predictor and target for anti-PD-1/PD-L1 therapy. *Front Immunol* 2022;13:1061394.
 76. Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, et al. TGF- β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. *Theranostics* 2020;10:1910.

77. Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Sosman JA, *et al.* Immunosuppressive IDO in cancer: Mechanisms of action, animal models, and targeting strategies. *Front Immunol* 2020;11:1185.
78. Bistrup A, Cabaltica C, Jalilie M, Wolfert R, Kim N. Evaluation of human secretoglobins and MIC-1 as serum diagnostic biomarkers for breast cancer. *Cancer Res* 2009;69:2005.
79. Passeri L, Marta F, Bassi V, Gregori S. Tolerogenic dendritic cell-based approaches in autoimmunity. *Int J Mol Sci* 2021;22:8415.
80. Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, *et al.* Inhibition of experimental asthma by indoleamine 2, 3-dioxygenase. *J Clin Invest* 2004;114:270-279.
81. Yin Q, Wang L, Yu H, Chen D, Zhu W, Sun C. Pharmacological effects of polyphenol phytochemicals on the JAK-STAT signaling pathway. *Front Pharmacol* 2021;12:716672.
82. Arumuggam N, Bhowmick NA, Rupasinghe HV. A review: phytochemicals targeting JAK/STAT signaling and IDO expression in cancer. *Phytother Res* 2015;29:805-817.
83. Noh KT, Chae SH, Chun SH, Jung ID, Kang HK, Park Y-M. Resveratrol suppresses tumor progression via the regulation of indoleamine 2, 3-dioxygenase. *Biochem Biophys Res Commun* 2013;431:348-53.
84. Gualdoni GA, Fuchs D, Zlabinger GJ, Gostner JM. Resveratrol intake enhances indoleamine-2, 3-dioxygenase activity in humans. *Pharmacol Rep* 2016;68:1065-1068.
85. Fujimura T, Mahnke K, Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. *J Dermatol Sci* 2010;59:1-6.
86. Saed SM, Abbas S, El Ansary MS, Abdelfattah W, Maurice KK, Mohamed ME, Koptan DMT. Phenotypic analysis of circulating myeloid derived suppressor cells and their subpopulations in egyptian females with breast cancer: A single-centre case-control study. *APJCP* 2024;25:257.
87. Zhao Y, Shao Q, Zhu H, Xu H, Long W, Yu B, *et al.* Resveratrol ameliorates Lewis lung carcinoma-bearing mice development, decreases granulocytic myeloid-derived suppressor cell accumulation and impairs its suppressive ability. *Cancer Sci* 2018;109:2677-26786.
88. Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, *et al.* HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. *Cancer Res* 2014;74:5723-5733.
89. Malabadi RB, Sadiya M, Kolkar KP, Mammadova SS, Chalannavar RK, Baijnath H, *et al.* Triple negative breast cancer (TNBC): Signalling pathways-role of plant-based inhibitors. *Res J Biol Pharm* 2024;10:028-71.
90. Han X, Zhao N, Zhu W, Wang J, Liu B, Teng Y. Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model. *Cell Immunol* 2021;368:104423.
91. Hamaidi I, Kim S. Sirtuins are crucial regulators of T cell metabolism and functions. *Exp Mol Med* 2022;54:207-215.
92. Craveiro M, Cretenet G, Mongellaz C, Matias MI, Caron O, de Lima MCP, *et al.* Resveratrol stimulates the metabolic reprogramming of human CD4+ T cells to enhance effector function. *Sci Signal* 2017;10:eal3024.
93. Yang M, Li Z, Tao J, Hu H, Li Z, Zhang Z, *et al.* Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells. *J Cancer Res Clin Oncol* 2021;147:1101-13.
94. He J, Qiu N, Zhou X, Meng M, Liu Z, Li J, *et al.* Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies. *Front Oncol* 2023;12:1007653.
95. Zhang Q, Yang C, Gao X, Dong J, Zhong C. Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy. *Phytother Res* 2024;38:776-796.
96. Zong Y, Deng K, Chong WP. Regulation of Treg cells by cytokine signaling and co-stimulatory molecules. *Front Immunol* 2024;15:1387975.
97. Yang Y, Paik JH, Cho D, Cho J-A, Kim C-W. Resveratrol induces the suppression of tumor-derived CD4+ CD25+ regulatory T cells. *Int Immunopharmacol* 2008;8:542-547.
98. Espinoza JL, Trung LQ, Inaoka PT, Yamada K, An DT, Mizuno S, *et al.* The repeated administration of resveratrol has measurable effects on circulating T-cell subsets in humans. *Oxid Med Cell Longev* 2017;2017:6781872.
99. Wang B, Sun J, Li X, Zhou Q, Bai J, Shi Y, Le G. Resveratrol prevents suppression of regulatory T-cell production, oxidative stress, and inflammation of mice prone or resistant to high-fat diet-induced obesity. *Nutr Res* 2013;33:971-981.
100. Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, *et al.* Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. *Aging (Albany NY)* 2020;12:8.
101. Malaguarnera L. Influence of Resveratrol on the Immune Response. *Nutrients* 2019;11:946.
102. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, *et al.* Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. *Cancer Res* 2011;71:3505-3515.
103. Lee-Chang C, Bodogai M, Martin-Montalvo A, Wejksza K, Sanghvi M, Moaddel R, *et al.* Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. *J Immunol* 2013;191:4141-4151.
104. Meng X, Zhou J, Zhao C-N, Gan R-Y, Li H-B. Health benefits and molecular mechanisms of resveratrol: A narrative review. *Foods* 2020;9:340.
105. Li Q, Huyan T, Ye L-J, Li J, Shi J-L, Huang Q-S. Concentration-dependent biphasic effects of resveratrol on human natural killer cells *in vitro*. *J Agric Food Chem* 2014;62:10928-10935.
106. Lee Y, Shin H, Kim J. *In vivo* anti-cancer effects of resveratrol mediated by NK cell activation. *J Innate Immun* 2021;13:94-106.
107. Pan J, Shen J, Si W, Du C, Chen D, Xu L, *et al.* Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway. *Oncotarget* 2017;8:65743.
108. Lu CC, Chen JK. Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. *J Cell Physiol* 2010;223:343-351.
109. Clément M-Vr, Hirpara JL, Chawdhury S-H, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. *Blood* 1998;92:996-1002.
110. Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M, Ravagnan G. Effects of resveratrol on human immune cell function. *Life Sci* 2001;70:81-96.
111. Delmas D, Hermetet F, Aires V. PD-1/PD-L1 checkpoints and resveratrol: A controversial new way for a therapeutic strategy. *Cancers* 2021;13:4509.
112. Janus-Bell E, Mangin PH. The relative importance of platelet integrins in hemostasis, thrombosis and beyond. *Haematologica* 2023;108:1734-1747.
113. Lucas J, Hsieh T-C, Halicka HD, Darzynkiewicz Z, Wu JM. Up-regulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF- κ B signaling. *Int J Oncol* 2018;53:1469-1480.
114. Hsieh TC, Wu JM. Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage ("SEE") Signal to Facilitate the Elimination of "Cold, Non-Responsive" Low PD-L1-Expressing Tumors by PD-L1 Blockade. *Int J Mol Sci* 2019;20:5969.
115. Li H, Seeram NP, Liu C, Ma H. Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1. *Front Oncol* 2022;12:995461.
116. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. *Ann N Y Acad Sci* 2011;1215:161-169.

117. Brown K, Theofanous D, Britton RG, Aburido G, Pepper C, Sri Undru S, Howells L. Resveratrol for the management of human health: How far have we come? A systematic review of resveratrol clinical trials to highlight gaps and opportunities. *Int J Mol Sci* 2024;25:747.
118. Erdogan CS, Vang O. Challenges in analyzing the biological effects of resveratrol. *Nutrients* 2016;8:353.
119. Mishra S, Amatya SB, Salmi S, Koivukangas V, Karihtala P, Reunanen J. Microbiota and extracellular vesicles in anti-PD-1/PD-L1 therapy. *Cancers* 2022;14:5121.
120. Li F, Han Y, Wu X, Cao X, Gao Z, Sun Y, *et al.* Gut microbiota-derived resveratrol metabolites, dihydroresveratrol and lunularin, significantly contribute to the biological activities of resveratrol. *Front Nutr* 2022;9:912591.
121. Luo B, An Q, Lei J, Tan D, Liu X, Li H, *et al.* Resveratrol amplifies the anti-tumor effect of α -PD-1 by altering the intestinal microbiome and PGD2 content. *Gut Microbes* 2025;17:2447821.
122. Ramírez-Garza SL, Laveriano-Santos EP, Marhuenda-Muñoz M, Storniolo CE, Tresserra-Rimbau A, Vallverdú-Queralt A, Lamuela-Raventós RM. Health effects of resveratrol: Results from human intervention trials. *Nutrients* 2018;10:1892.
123. Shaito A, Posadino AM, Younes N, Hasan H, Halabi S, Alhababi D, *et al.* Potential adverse effects of resveratrol: A literature review. *Int J Mol Sci* 2020;21:2084.
124. Truong VL, Jun M, Jeong WS. Role of resveratrol in regulation of cellular defense systems against oxidative stress. *Biofactors* 2018;44:36-49.
125. Pezzuto JM, Kondratyuk TP, Ogas T. Resveratrol derivatives: A patent review (2009–2012). *Expert Opin Ther Pat* 2013;23:1529-1246.
126. Alsaikhan F. The synergistic effect of resveratrol and curcumin on oncogenic lncRNA MAPT-IT1 and ferroptosis-related genes in breast cancer. *Naunyn Schmiedeberg Arch Pharmacol* 2025;1-18.
127. Ding B, Li J, Yan J-L, Jiang C-Y, Qian L-B, Pan J. Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling. *Front Immunol* 2025;16:1515605.
128. Gao Y, Wang YY, Di Wang B, Hu QY, Jiang JR, Feng B, *et al.* Mechanism of action of resveratrol affecting the biological function of breast cancer through the glycolytic pathway. *World J Oncol* 2025;16:375.
129. Li P, Liang Y, Ma X. Functional role of resveratrol in inducing apoptosis in breast cancer subtypes via inhibition of intracellular fatty acid synthase. *Molecules* 2025;30:2891.
130. Toliopoulos IK, Simos YV, Oikonomidis S, Karkabounas SC. Resveratrol diminishes platelet aggregation and increases susceptibility of K562 tumor cells to natural killer cells. *Indian J Biochem Biophys* 2013;50:14-8.
131. Chen L, Yang S, Liao W, Xiong Y. Modification of antitumor immunity and tumor microenvironment by resveratrol in mouse renal tumor model. *Cell Biochem Biophys* 2015;72:617-625.
132. Zhu W, Qin W, Zhang K, Rottinghaus GE, Chen Y-C, Kliethermes B, Sauter ER. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. *Nutr Cancer* 2012;64:393-400.
133. Lin C-C, Chin Y-T, Shih Y-J, Chen Y-R, Chung Y-Y, Lin C-Y, *et al.* Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells. *J Dent Sci* 2019;14:255-262.
134. Pradhan R, Paul S, Acharya SS, Sinha S, Dash SR, Kundu CN. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis. *J Nutr Biochem* 2024;125:109568.